Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAAT3 | P53816 | 1/20 | 0.51 |
| ▸ | PLAAT5 | Q96KN8 | 1/20 | 0.51 |
| ▸ | PLAAT2 | Q9NWW9 | 1/20 | 0.51 |
| ▸ | PLAAT4 | Q9UL19 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.49 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.49 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.48 |
| ▸ | CYP4F11 | Q9HBI6 | 1/20 | 0.48 |
| ▸ | CYP4F12 | Q9HCS2 | 1/20 | 0.48 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18657080 | 0.95 | CYP4Z1 (0.49) | PLAAT3PLAAT5PLAAT2PLAAT4TDP1 | |
| SCHEMBL7415485 | 0.93 | TSHR (0.56) | PLAAT3PLAAT5PLAAT2PLAAT4TDP1 | |
| SCHEMBL18373121 | 0.93 | HPGD (0.50) | PLAAT3PLAAT5PLAAT2PLAAT4TDP1 | |
| SCHEMBL16672973 | 0.93 | HPGD (0.50) | PLAAT3PLAAT5PLAAT2PLAAT4TDP1 | |
| SCHEMBL22921868 | 0.92 | TSHR (0.58) | ALDH1A1TSHREPHX2CYP4A11CYP4F2 | |
| SCHEMBL2569441 | 0.89 | L3MBTL1 (0.55) | PLAAT3PLAAT5PLAAT2PLAAT4TDP1 | |
| SCHEMBL23843382 | 0.88 | POLB (0.54) | ALDH1A1LMNAMAPT | |
| SCHEMBL9235577 | 0.88 | L3MBTL1 (0.55) | PLAAT3PLAAT5PLAAT2PLAAT4TDP1 | |
| SCHEMBL7472142 | 0.88 | TDP1 (0.43) | PLAAT3PLAAT5PLAAT2PLAAT4TDP1 | |
| SCHEMBL15471696 | 0.86 | CYP4A11 (0.48) | TDP1ALDH1A1EPHX2CYP4A11CYP4F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260008740-A1 | BEXAROTENE DERIVATIVES AND THEIR USE IN TREATING CANCER | DJ Therapeutics LLC (US) | 2026-01-08 | — | — | US | disclosed |
| US-12338214-B2 | Bexarotene derivatives and their use in treating cancer | DJ Therapeutics LLC (US) | 2025-06-24 | — | — | US | disclosed |
| WO-2024137915-A1 | BORON-CONTAINING CYCLIC EMISSIVE COMPOUNDS AND COLOR CONVERSION FILM CONTAINING THE SAME | NITTO DENKO CORPORATION (US) | 2024-06-27 | — | — | WO | disclosed |
| WO-2024119026-A1 | BORON-CONTAINING CYCLIC EMISSIVE COMPOUNDS AND COLOR CONVERSION FILM CONTAINING THE SAME | NITTO DENKO CORPORATION (JP) | 2024-06-06 | — | — | WO | disclosed |
| WO-2023158976-A1 | BORON-CONTAINING CYCLIC EMISSIVE COMPOUNDS AND COLOR CONVERSION FILM CONTAINING THE SAME | NITTO DENKO CORPORATION (JP) | 2023-08-24 | — | — | WO | disclosed |
| WO-2022178427-A9 | BORON-CONTAINING CYCLIC EMISSIVE COMPOUNDS AND COLOR CONVERSION FILM CONTAINING THE SAME | NITTO DENKO CORPORATION (JP) | 2023-07-27 | — | — | WO | disclosed |
| WO-2022178427-A1 | BORON-CONTAINING CYCLIC EMISSIVE COMPOUNDS AND COLOR CONVERSION FILM CONTAINING THE SAME | NITTO DENKO CORPORATION (JP) | 2022-08-25 | — | — | WO | disclosed |
| US-20210363093-A1 | BEXAROTENE DERIVATIVES AND THEIR USE IN TREATING CANCER | DAWN SCIENTIFIC PHARMACEUTICALS, LLC | 2021-11-25 | — | — | US | disclosed |
| US-20210363093-A1 | BEXAROTENE DERIVATIVES AND THEIR USE IN TREATING CANCER | DAWN SCIENTIFIC PHARMACEUTICALS, LLC | 2021-11-25 | — | — | US | disclosed |
| WO-2021188762-A1 | BORON-CONTAINING CYCLIC EMISSIVE COMPOUNDS AND COLOR CONVERSION FILM CONTAINING THE SAME | NITTO DENKO CORPORATION (JP) | 2021-09-23 | — | — | WO | disclosed |
| WO-2007000550-A2 | NOVEL INDOLINE COMPOUNDS | LABORATOIRES FOURNIER S.A. (FR) | 2007-01-04 | — | — | WO | disclosed |
| WO-2006005486-A1 | SULFONAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-01-19 | — | — | WO | disclosed |
| US-6713515-B2 | ADMINISTERING BENZYL, NAPHTHYL ACID DERIVATIVES | BRISTOL MYERS SQUIBB COMPANY | 2004-03-30 | — | — | US | disclosed |
| US-6624154-B1 | Invention relates to compositions comprising a retinoid X receptor agonist and an agent capable of activating protein kinase A. The invention also relates to methods of treating hyperproliferative diseases by administering a retinoid X | BRISTOL-MYERS SQUIBB COMPANY | 2003-09-23 | — | — | US | disclosed |
| US-20020120006-A1 | Retinoic acid receptor antagonists as promoters of angiogenesis | BRISTOL-MYERS SQUIBB COMPANY | 2002-08-29 | — | — | US | disclosed |
| WO-2002022113-A2 | RETINOIC ACID RECEPTOR ANTAGONISTS AS PROMOTERS OF ANGIOGENESIS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-03-21 | — | — | WO | disclosed |
| EP-1173061-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF HYPERPROLIFERATIVE DISEASES | Bristol-Myers Squibb Company (US) | 2002-01-23 | — | — | EP | disclosed |
| WO-2000064260-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF HYPERPROLIFERATIVE DISEASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-11-02 | — | — | WO | disclosed |
| WO-2000059861-A1 | SELECTIVE RETINOIC ACID ANALOGS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-10-12 | — | — | WO | disclosed |
| US-3931279-A | 5-Oxa prostaglandin F2.sub.α analogs | THE UPJOHN COMPANY (US) | 1976-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020120006-A1 | Retinoic acid receptor antagonists as promoters of angiogenesis | RARB, RARG, RARA | PLAAT3 738/4885PLAAT5 774/4885PLAAT2 921/4885 |
| US-12338214-B2 | Bexarotene derivatives and their use in treating cancer | C3AR1, CXCR3, CCR7 | PLAAT3 2351/4885PLAAT5 3153/4885PLAAT2 3714/4885 |
| US-20210363093-A1 | BEXAROTENE DERIVATIVES AND THEIR USE IN TREATING CANCER | ENPP2, XPA, CCR8 | PLAAT3 424/4885PLAAT5 972/4885PLAAT2 896/4885 |
| US-20260008740-A1 | BEXAROTENE DERIVATIVES AND THEIR USE IN TREATING CANCER | CXCR3, CCR6, CCR9 | PLAAT3 1261/4885PLAAT5 3051/4885PLAAT2 2775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.